Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report
AstraZeneca's new chief executive, Pascal Soriot wants the diabetes marketing teams from the AstraZeneca and Bristol-Myers Squibb partnership to think deep thoughts about how they are going to sell more products. To do that, they have been put together and the team then sequestered in their own home away from the distractions of their respective companies.
Will the truth set AstraZeneca ($AZN) free? It might keep new CEO Pascal Soriot clear of big expectations for another year or so. Perhaps that's why the company laid out its shortcomings with its 2012 earnings announcement. Sales are falling, earnings are falling--and both will continue on that path, with profits declining even more than revenues.
Today's look at AstraZeneca's ($AZN) bleak 2012 numbers highlights the market-crunching wallop many of the world's biggest pharma companies have suffered as megablockbusters like Plavix and Singulair have gone off patent. But a new analysis from EvaluatePharma concludes that the industry giants will have almost as much at stake again when the 2015 patent cliff arrives.
AstraZeneca's bleak 2013 forecast leaves the Big Pharma company somewhere between a rock and a bargaining table. And today new CEO Pascal Soriot laid out a path of financial crumbs that led analysts to the simple conclusion that deal-making is afoot.
Sweden's Orexo has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a new therapy to treat respiratory diseases.
AstraZeneca CEO Pascal Soriot is banking on a deep pipeline of respiratory meds to help revive the beleaguered drug giant.
A heightened flu season and a spate of newly approved influenza vaccines have experts wondering what else they can do to mitigate or prevent the seasonal illness. Next up: A universal flu vaccine administered every 5 to 10 years to fight multiple virus strains and eradicate the need for annual shots.
While Big Pharma companies have been chopping at their own R&D shops while looking more often to outside academic experts to help them find the next blockbuster drug, Vanderbilt University has capitalized on the trend.
Tamoxifen is best known as AstraZeneca's now off-patent breast cancer drug, but in perhaps a rather surprising outcome, it also improves muscle strength in a mouse version of Duchenne muscular dystrophy.